We are excited to share that our client 4J Therapeutics was the recipient of the Biomedical Advanced Research and Development Authority (BARDA) $313 MILLION contract 🎉

The project we specifically helped 4J Therapeutics through the process of applying for this contract is focused on developing a new type of antiviral treatment using locked nucleic acid (LNA) technology. The treatment targets a specific, essential part of the influenza A virus (IAV), making it effective against all known strains, including drug-resistant ones. The therapy is designed to destroy the virus’s RNA and prevent it from mutating into resistant forms. The project aims to advance this antiviral through clinical trials, with potential applications for other viruses in the future, offering a broad and fast-acting defense against pandemics.

Words from Consultant James Cross and his experience working on this massive deal:

As a consultant at FreeMind, I have had the privilege of working with 4J Therapeutics for nearly a year, supporting their efforts to secure funding for their groundbreaking Influenza A virus (IAV) treatment. I am thrilled that 4J Therapeutics has achieved a significant milestone by securing a substantial contract with the Biomedical Advanced Research and Development Authority (BARDA).

This success is a testament to the hard work, dedication, and perseverance of the 4J Therapeutics team. The intense nature of our collaboration was driven by the immense potential of their innovative technology and the significant impact it could have on global health. The BARDA contract, totaling approximately $315 million, will enable 4J Therapeutics to advance their therapeutic through various stages of development, bringing us one step closer to a commercial product that could save countless lives.

Throughout this journey, I worked closely with 4J Therapeutics, providing guidance and support as they navigated the complex landscape of government contracts. The project was demanding, with tight deadlines and high stakes, but our shared commitment to the cause kept us focused and motivated. I found myself dedicating significant time and resources, often working on weekends and even while abroad, to ensure the success of this collaboration.

While the challenges were significant, the potential impact of our work drove me forward. As a consultant in the life sciences industry, my primary motivation is to make a difference in global health. Knowing that our efforts could lead to a treatment for a potentially dangerous viral threat is incredibly rewarding and makes the long hours and difficult moments worthwhile.

The success of this collaboration can be attributed to several key factors, including the cutting-edge science behind their lead influenza A LNA, the expertise and adaptability of the FreeMind team, and the unwavering dedication of both 4J Therapeutics and FreeMind. By working together seamlessly, we were able to overcome challenges and secure this significant funding opportunity.